Edgewise Therapeutics Inc (EWTX)

Currency in USD
12.68
-0.27(-2.08%)
Closed·
After Hours
12.54-0.14(-1.10%)
·
EWTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
EWTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.4613.18
52 wk Range
10.6038.12
Key Statistics
Prev. Close
12.95
Open
12.99
Day's Range
12.46-13.18
52 wk Range
10.6-38.12
Volume
568.06K
Average Volume (3m)
829.25K
1-Year Change
-21.68%
Book Value / Share
4.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EWTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
39.08
Upside
+208.23%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Edgewise Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Edgewise Therapeutics Inc Company Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics Inc SWOT Analysis


Novel Therapies
Edgewise Therapeutics develops innovative treatments for rare muscle disorders, with lead candidate EDG-7500 in clinical trials for hypertrophic cardiomyopathy
Clinical Milestones
Explore the company's catalyst-rich 2025, featuring crucial data readouts for EDG-7500 and sevasemten in muscular dystrophy programs
Market Potential
Delve into Edgewise's positioning in the lucrative rare disease market, addressing significant unmet needs in HCM and muscular dystrophy
Analyst Outlook
Learn about the bullish sentiment surrounding EWTX, with price targets ranging from $30 to $56, reflecting substantial upside potential
Read full SWOT analysis

Compare EWTX to Peers and Sector

Metrics to compare
EWTX
Peers
Sector
Relationship
P/E Ratio
−8.9x−3.5x−0.5x
PEG Ratio
2.350.030.00
Price/Book
2.3x4.4x2.6x
Price / LTM Sales
-1.5x3.3x
Upside (Analyst Target)
227.3%230.5%43.4%
Fair Value Upside
Unlock1.3%7.1%Unlock

Analyst Ratings

10 Buy
2 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 39.08
(+208.23% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.34 / -0.42
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

EWTX Income Statement

People Also Watch

247.45
AVAV
-4.68%
18.23
SRPT
+1.50%
138.73
KRYS
+1.93%
11.16
DYN
-0.27%
7.55
ASPN
-0.33%

FAQ

What Stock Exchange Does Edgewise Therapeutics Trade On?

Edgewise Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Edgewise Therapeutics?

The stock symbol for Edgewise Therapeutics is "EWTX."

What Is the Edgewise Therapeutics Market Cap?

As of today, Edgewise Therapeutics market cap is 1.33B.

What Is Edgewise Therapeutics's Earnings Per Share (TTM)?

The Edgewise Therapeutics EPS (TTM) is -1.55.

When Is the Next Edgewise Therapeutics Earnings Date?

Edgewise Therapeutics will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is EWTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Edgewise Therapeutics Stock Split?

Edgewise Therapeutics has split 0 times.

How Many Employees Does Edgewise Therapeutics Have?

Edgewise Therapeutics has 117 employees.

What is the current trading status of Edgewise Therapeutics (EWTX)?

As of 09 Aug 2025, Edgewise Therapeutics (EWTX) is trading at a price of 12.68, with a previous close of 12.95. The stock has fluctuated within a day range of 12.46 to 13.18, while its 52-week range spans from 10.60 to 38.12.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.